5.62
0.12 (2.18%)
| Penutupan Terdahulu | 5.50 |
| Buka | 5.23 |
| Jumlah Dagangan | 14,904 |
| Purata Dagangan (3B) | 45,501 |
| Modal Pasaran | 171,371,216 |
| Harga / Jualan (P/S) | 4.96 |
| Julat 52 Minggu |
| Margin Keuntungan | -205.46% |
| Margin Operasi (TTM) | -95.21% |
| EPS Cair (TTM) | -1.92 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 41.50% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | -43.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.84 M |
| Pulangan Atas Aset (ROA TTM) | -92.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | TriSalus Life Sciences, Inc. | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 5.0 |
| Purata | 0.88 |
|
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 54.94% |
| % Dimiliki oleh Institusi | 13.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wealthcare Advisory Partners Llc | 31 Dec 2024 | 643,740 |
| Graypoint Llc | 31 Dec 2024 | 120,355 |
| Msd Partners, L.P. | 31 Dec 2024 | 39,999 |
| Connecticut Wealth Management, Llc | 31 Dec 2024 | 22,303 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 11.00 (Roth MKM, 95.73%) | Beli |
| 11.00 (Canaccord Genuity, 95.73%) | Beli | |
| Median | 11.00 (95.73%) | |
| Rendah | 10.00 (Lake Street, 77.94%) | Beli |
| Purata | 10.67 (89.86%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 5.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 28 Mar 2025 | 11.00 (95.73%) | Beli | 5.62 |
| Lake Street | 13 Feb 2025 | 10.00 (77.94%) | Beli | 5.53 |
| Roth MKM | 24 Jan 2025 | 11.00 (95.73%) | Beli | 5.18 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |